When administered near the time of training, protein synthesis inhibitors such as anisomycin impair later memory. A common interpretation of these findings is that memory consolidation requires new protein synthesis initiated by training. However, recent findings support an alternative interpretation that abnormally large increases in neurotransmitter release after injections of anisomycin may be responsible for producing amnesia. In the present study, a local anesthetic was administered prior to anisomycin injections in an attempt to mitigate neurotransmitter actions and thereby attenuate the resulting amnesia. Rats received lidocaine and anisomycin injections into the amygdala 130 and 120 min, respectively, prior to inhibitory avoidance training. Memory tests 48 h later revealed that lidocaine attenuated anisomycin-induced amnesia. In other rats, in vivo microdialysis was performed at the site of amygdala infusion of lidocaine and anisomycin. As seen previously, anisomycin injections produced large increases in release of norepinephrine in the amygdala. Lidocaine attenuated the anisomycin-induced increase in release of norepinephrine but did not reverse anisomycin inhibition of protein synthesis, as assessed by c-Fos immunohistochemistry. These findings are consistent with past evidence suggesting that anisomycin causes amnesia by initiating abnormal release of neurotransmitters in response to the inhibition of protein synthesis.
Introduction
The predominant model for the molecular basis of memory is that memory formation occurs in two stages: an early transient stage independent of protein synthesis and a long-term memory phase dependent on training-initiated de novo protein synthesis (cf.: Davis & Agranoff, 1966; Davis & Squire, 1984; Dudai, 2002; Izquierdo et al., 2002; Kandel, 2001; Nader, 2003; Schafe & LeDoux, 2000) . Support for this model comes from numerous studies in which protein synthesis inhibitors such as anisomycin administered near the time of training have no effect on memory tested during the first few hours after training but impair memory tested at longer time intervals.
However, evidence obtained over the past 40 years suggests that drugs that inhibit protein synthesis may lead to secondary dysfunctions in neural activity that might produce amnesia. Several studies have suggested that protein synthesis inhibitors interfere with neurotransmitter synthesis and release. For example, early studies showed that protein synthesis inhibitors reduced the activity of tyrosine hydroxylase, the rate-limiting enzyme involved in the synthesis of norepinephrine and dopamine from tyrosine (Flexner & Goodman, 1975; Flexner, Serota, & Goodman, 1973; Goodman, Flexner, & Flexner, 1975) . Recent studies found that intra-amygdala and intra-hippocampal injections of anisomycin induced abnormally large increases in the release of norepinephrine, dopamine, serotonin, and acetylcholine at the site of the injection (Canal, Chang, & Gold, 2007; Qi & Gold, 2009 ). Related to these findings is evidence that many neurotransmitter-related drugs and hormones reverse amnesias associated with protein synthesis inhibitors and do so without reversing the extent of inhibition of protein synthesis (cf.: Davis & Squire, 1984; Gold, 2008; Martinez, Jensen, & McGaugh, 1981 ).
The present study tested whether a local anesthetic, lidocaine, would attenuate anisomycin-related memory impairments by inhibiting the anisomycin-induced increases in norepinephrine release, though likely not baseline release (Pan, Chen, Tsai, & Liao, 1996) . Since the time course for anterograde amnesia observed with lidocaine is shorter than that for anisomycin, we were able to adjust the timing of the injections such that lidocaine had no 1074-7427/$ -see front matter Ó 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.nlm.2011.03.007
